Rutgers University of New Jersey will enroll more than 200 children between the ages of 6 months and 11 years to participate in the COVID-19 vaccine trial for Pfizer and its German partner BioNotech.
College Announced Thursday It has been selected as a clinical trial site for Pfizer-BioNTech’s global research study to “evaluate the efficacy” of two-dose COVID-19 vaccine companies in children.
The Pediatric Clinical Research Center at Rutgers Robert Wood Johnson Medical School in New Brunswick is one of several clinical trial sites for pediatric studies and the only testing site in the Garden State.
Rutgers said that it will be for 100 children from 5 to 12 years old, children aged 2 to 5 and children aged 5 to 50 years ranging from 6 months to 2 years old.
According to the university, 4,644 children worldwide have been slated to participate in the program.
Trial participants will be randomly selected to receive two doses of Pfizer’s coronavirus vaccine or a placebo.
Six months after the second dose, participants will be offered “unread” and “the vaccine will be offered to those who have received the placebo,” the school said.
“Children can become ill with COVID-19 and spread the virus to others even if they are asymptomatic. Most children experience mild or no symptoms, some children may become seriously ill and have long-term effects, ”a statement by co-head investigator Simon Lee, Associate Professor of Pediatrics at Rutgers Robert Wood Johnson Medical School said in.
Lee said, “Vaccination in all age groups COVID-19 vaccination is important to prevent the global progression of the disease. Vaccination will also help us make our children feel safe to resume school and daily activities.”
Rutgers has previously served twice as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it tested vaccines for both Modern and Johnson & Johnson.
Meanwhile, Pfizer-BioNtech announced on Friday that they had applied for 16 and older people for their COVID-19 vaccine for full regulatory approval from the Food and Drug Administration.
The companies are the first Coronavirus vaccine manufacturer in the country to apply for full approval.
In addition, the partners have applied to the FDA to extend the current emergency authorization for their vaccines to people between the ages of 12 and 15 years.
Leave a Reply